CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
Predicting the response to chemotherapy is a major goal of cancer research. Here the authors use CRISPR knockout screens in pancreatic ductal adenocarcinoma cells to identify deletions synergistic with MEK inhibitors.
Guardado en:
Autores principales: | Karol Szlachta, Cem Kuscu, Turan Tufan, Sara J. Adair, Stephen Shang, Alex D. Michaels, Matthew G. Mullen, Natasha Lopes Fischer, Jiekun Yang, Limin Liu, Prasad Trivedi, Edward B. Stelow, P. Todd Stukenberg, J. Thomas Parsons, Todd W. Bauer, Mazhar Adli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5878576fa2b34029942f52a332a9c423 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Live cell imaging of low- and non-repetitive chromosome loci using CRISPR-Cas9
por: Peiwu Qin, et al.
Publicado: (2017) -
A microfluidics platform for combinatorial drug screening on cancer biopsies
por: Federica Eduati, et al.
Publicado: (2018) -
MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery
por: David J. Wooten, et al.
Publicado: (2021) -
Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity
por: Ding X, et al.
Publicado: (2012) -
Liquid crystalline assembly for potential combinatorial chemo–herbal drug delivery to lung cancer cells
por: Abdelaziz HM, et al.
Publicado: (2019)